Multiple myeloma burden and risk factors in China vs. high-income Asia Pacific: a macro-micro analysis
Frontiers in Public Health · 24.03.2026 · 14
DOI: 10.3389/fpubh.2026.1784817 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Public Health, online erschienen am 24.03.2026. Verfasst von Limin Chai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hos…. Hauptthemen laut MEDLINE: Multiple Myeloma, Cost of Illness. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Multiple myeloma (MM) presents a growing public health challenge in Asia, yet evidence on its epidemiology and risk factors in transitioning economies like China is limited. This study aimed to compare the disease burden, risk factors, and future trends of multiple myeloma between China and the High-Income Asia Pacific (HIC AP) region.
Methods
We conducted an integrated analysis combining data from the Global Burden of Disease (GBD) study 2023 (1993–2023) with a matched case-control study at a tertiary cancer center in China (2021–2025). The case-control component included 235 newly diagnosed MM cases and 235 healthy controls. Exposures of interest were sex, age, body mass index (BMI), and income level. Main outcomes included age-standardized incidence (ASIR), mortality (ASMR), and disability-adjusted life years (DALYs) rates (ASDR); individual-level risk associations; and Bayesian projections to 2040.
Results
From 1993 to 2023, China's ASIR increased by 175% (from 0.34 to 0.94 per 100 000), while its ASMR plateaued after 2,000. The HIC AP region maintained high but stable ASIRs (2.00 to 2.13 per 100 000) alongside declining ASMRs. In the case-control study, older age (50–69 years: adjusted odds ratio [aOR], 6.69; 95% confidence interval [CI], 4.08–10.99; ≥70 years: aOR, 6.10; 95% CI, 3.30–11.27) and male sex (aOR, 1.59; 95% CI, 1.06–2.37) were significant risk factors. Sex-stratified analysis revealed that higher BMI (24–27.9 kg/m 2 ) was associated with increased risk in males (aOR, 2.14; 95% CI, 1.19–3.85) but not in females (aOR, 0.86; 95% CI, 0.45–1.64). Income level showed no significant association. Projections indicate China's ASIR will continue rising to 2.55 per 100 000 by 2,040 with declining ASMR, while the HIC AP burden remains high and stable.
Conclusion
China exhibits transitional MM epidemiology characterized by rapidly rising incidence and plateauing mortality, driven by aging and improved healthcare access. The identified sex-specific association between BMI and myeloma risk highlights population heterogeneity. These findings underscore the need for tailored prevention and control strategies for Asia's evolving disease landscape.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China.
- Department of Hematology, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China.
Zitieren
APA
Chai, L., Guo, Y., He, L., Yang, A., Su, L., Wang, J., & Yang, J. (2026). Multiple myeloma burden and risk factors in China vs. high-income Asia Pacific: a macro-micro analysis. Frontiers in Public Health, 14. https://doi.org/10.3389/fpubh.2026.1784817
Vancouver
Chai L, Guo Y, He L, Yang A, Su L, Wang J, et al. Multiple myeloma burden and risk factors in China vs. high-income Asia Pacific: a macro-micro analysis. Frontiers in Public Health. 2026;14. doi:10.3389/fpubh.2026.1784817
BibTeX
@article{Chai2026,
author = {Chai, Limin and Guo, Yimeng and He, Linxiu and Yang, Aluo and Su, Liping and Wang, Jingrong and Yang, Jing},
title = {Multiple myeloma burden and risk factors in China vs. high-income Asia Pacific: a macro-micro analysis},
journal = {Frontiers in Public Health},
year = {2026},
volume = {14},
doi = {10.3389/fpubh.2026.1784817}
}
EUVIMED